International Journal of Drug Delivery Technology
Volume 14, Issue 2

Lipid Nanoemulgel Therapy for the Treatment of Keratoconjunctivitis Sicca: Cyclosporine Formulation Characterization and In-vitro Evaluation

Phadatare Suvarna P1*, Kurumkar Pritish P2, Wanegaonkar Anjali M1, Jadhav Varsha M1

1Department of Pharmaceutics, Bharati Vidyapeeth’s College of Pharmacy, Navi Mumbai, Maharashtra, India.

2Shri. D. D. Vispute College of Pharmacy & Research Center, Raigad, Maharashtra, India. 

Received: 20th December, 2023; Revised: 16th February, 2024; Accepted: 19th May, 2024; Available Online: 25th June, 2024 

ABSTRACT

Nanoparticulate carrier systems play a significant part in enhancing ocular bioavailability. Emulgels are a potential new delivery method for the administration of lipophilic drugs like cyclosporine A (CsA). In the present research work, CsA, the immunomodulatory drug with a wide safety profile, has been formulated into nanoemulgel for treating vision-threatening ocular surface disorder viz. Keratoconjunctivitis sicca. The objective of this study was to prepare lipid-based nanoemulsion gel of CsA aiming to prolong corneal residence time and increase ocular bioavailability. Ophthalmic nanoemulgel was prepared using suitable vehicles, preservatives, hydrophilic and lipophilic emulsifiers viz croduret 40, poloxamers, spans, polyethylene glycol, polyoxyethylene 40 stearate, etc., by probe sonication method. It was evaluated for physical appearance, particle size, pH, viscosity, drug release, assay, and stability, etc. using appropriate methods. The pH and osmolarity of transparent ocular liquigel were 7.2 and 155 mOsm/L respectively. The particle size analysis and cryo scanning electron microscopic images of ocular nanoemulgel showed a monodisperse system containing a globule mean size of 190.2 ± 8.93 nm. The drug content was 99.5% w/w and the in-vitro diffusion studies showed that the medication was released for 6 hours; followed first-order kinetics with a high regression coefficient (r2) of 0.982. The lipid carrier-based topical cyclosporine ophthalmic liquigel was developed and evaluated. The in-vitro study has shown uniform, smooth-surfaced globules of size < 200 nm and prolonged drug release up to 6 hours; thus indicating increased corneal residence by nanocarrier-based gel system.

Keywords: Cyclosporine, Dry eye disease, Ophthalmic delivery, Lipid nanoemulsion gel, Drug delivery systems, Ocular surface disorder, Hydrophilic, Lipophilic surfactants.

International Journal of Drug Delivery Technology (2024); DOI: 10.25258/ijddt.14.2.16

How to cite this article: Suvarna PP, Pritish KP, Anjali WM, Varsha JM. Lipid Nanoemulgel Therapy for the Treatment of Keratoconjunctivitis Sicca: Cyclosporine Formulation Characterization and In-vitro Evaluation. International Journal of Drug Delivery Technology. 2024;14(2):709-713.

REFERENCES

  1. Bucolo C, Drago F, Salomone S. Ocular drug delivery: a clue from Front Pharmacol. 2012; 3:188. doi: 10.3389/ fphar.2012.00188, PMID 23125835.
  2. Rajab NA, Jawad MS. Impact of Lipid Type and Ratio in Rizatriptan Benzoate Nanostructured Lipid International Journal of Drug Delivery Technology. 2023;13(1):112-119. doi: 10.25258/ijddt.13.1.17
  3. Simon B. Lipid and polymeric colloidal carriers for ocular drug In: Tamilvanan S, Benita S, editor. Microencapsulation- methods and industrial applications. 2nd ed. New York: CRC Press Taylor and Francis group; 2006. p. 587-623.
  4. Narala S, Komanduri N, Nyavanandi D, Youssef AA, Mandati P, Alzahrani A, Kolimi P, Narala N, Repka MA. Hard gelatin capsules containing hot melt extruded solid crystal suspension of carbamazepine for improving dissolution: Preparation and in vitro Journal of Drug Delivery Science and Technology. 2023 Apr 1; 82:104384. DOI: https://doi.org/10.1016/j.jddst.2023.104384
  5. Scott CA, Catania LJ. Optometric clinical practice guideline – Care of the patient with Ocular surface disorders, by American Optometric Association. USA; 2011.
  6. Phadatare SP, Momin M, Singh KK. A comprehensive review on dry eye disease: diagnosis, medical management, recent developments and future Advances in Pharmaceutics 2015. Hindwi Publishing House, 2015:704946
  7. Lemp MA, Baudouin C, Baum J. et al. The definition and classification of dry eye disease: report of the definition and classification subcommittee of the international dry eye workshop. Ocul Surf 2007;5:75–92. doi: 1016/s1542- 0124(12)70082-4, PMID 17508117.
  8. Gan L, Wang J, Jiang M, Bartlett H, Ouyang D, Eperjesi F, et Recent advances in topical ophthalmic drug delivery with lipid- based nanocarriers. Drug Discov Today. 2013;18(5-6):290-7. doi: 10.1016/j.drudis.2012.10.005, PMID 23092895.
  9. Majeed SN, Zaman NA. Adenovirus and Bacterial Pathogens Isolated from Eye International Journal of Pharmaceutical Quality Assurance. 2020;11(4):538-541. doi: 10.25258/ijpqa.11.4.15
  10. Khan NT. Cyclosporin A Production from Tolipocladium inflatum. Gen Med. 2017;5:294.
  11. Rockville: the United States pharmacopeia. NF 33; The United States Pharmacopeia and National Formulary. 31st 2015:38.
  12. Wang K, Jianping Qi, Weng T.et al. Enhancement of oral bioavailability of cyclosporine A: comparison of various nanoscale drug-delivery systems. Int J Nanomedicine. 2014; 9: 4991-99. doi: 2147/IJN.S72560 PMID: 25378925
  13. Donnenfeld E, Pflugfelder Topical ophthalmic cyclosporine: pharmacology and clinical uses. Surv Ophthalmol. 2009;54(3):321-doi: 10.1016/j.survophthal.2009.02.002, PMID 19422961.
  14. Yavuz B, Bozdağ Pehlivan S, Unlü An overview on d r y eye t reat ment: approaches for cyclospor i n A delivery. ScientificWorldJournal. 2012;2012:194848. doi: 10.1100/2012/194848, PMID 22619624.
  15. Begur M, Pai VK, Gowda DV, Srivastava A, Raghundan HV. Shinde CG. Enhanced permeability of cyclosporine from a transdermally applied nanoemulgel. Sinica: Pelagia Research Library, Der Pharmacia 2015; 9(2): 69-79.
  16. Zhao X., Zhou YQ, Potharaju S, Lou H and Sun, Almoazen H, Johnson, et al. Development of a self micro-emulsifying tablet of cyclosporine- A by the liquisolid compact technique. H and Brunson, E. Int J Pharm Sci Res. 2011;2(9):2299-308.
  17. Ayalasomayajula LU, Patro CS, Raul SK. Selection and Characterization of a Nanoemulsion of Poorly Soluble Drug by Applying Box-Behnken Design and Converting it into a Nanoemulgel for Topical International Journal of Pharmaceutical Quality Assurance. 2024;15(1):1-10. doi: 10.25258/ijpqa.15.1.01
  18. Kim JW, Shin HJ, Yang SG. Cyclosporin- containing pharmaceutical composition. U.S Patent 5980939:1999.
  19. National Center for Biotechnology Information. PubChem database. Cyclosporine A, compound CID: 123134270.
  20. Nasser ST, Abdulrassol AA, Ghareeb Design, Preparation, and In-vitro Evaluation of Novel Ocular Antifungal Nanoemulsion Using Posaconazole as a Model Drug. International Journal of Drug Delivery Technology. 2021;11(3):1058-1064. doi: 10.25258/ ijddt.11.3.71
  21. Li X, Nie SF, Kong J, Li N, Ju CY, Pan A controlled-release ocular delivery system for ibuprofen based on nanostructured lipid carriers. Int J Pharm. 2008;363(1-2):177-82. doi: 10.1016/j. ijpharm.2008.07.017, PMID 18706987.
  22. Jiao J. Polyoxyethylated nonionic surfactants and their applications in topical ocular drug delivery. Adv Drug Deliv Rev. 2008;60(15):1663-73. doi: 1016/j.addr.2008.09.002, PMID 18845195.
  23. Kolimi P, Narala S, Youssef AA, Nyavanandi D, Dudhipala N. A systemic review on development of mesoporous nanoparticles as a vehicle for transdermal drug delivery. Nanotheranostics. 2023;7(1):70. DOI: https://doi.org/10.7150/ntno.77395
  24. Danaei M, Dehghankhold M, Ataei S, Hasanzadeh Davarani F, Javanmard R, Dokhani A, et al. Impact of particle size and polydispersity index on the clinical applications of lipidic nanocarrier Pharmaceutics. 2018;10(2):57. doi: 10.3390/ pharmaceutics10020057, PMID 29783687.